BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 22988651)

  • 21. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A; Kroth J; Hauschild A; Dirschka T
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous side-effects of EGFR inhibitors and their management.
    Ehmann LM; Ruzicka T; Wollenberg A
    Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Common side effects of anti-EGFR therapy: acneform rash.
    Sipples R
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Acneiform eruptions induced by cetuximab].
    Walon L; Gilbeau C; Lachapelle JM
    Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
    Treudler R; Zouboulis CC
    Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753
    [No Abstract]   [Full Text] [Related]  

  • 26. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
    Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
    Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Grover's disease induced by cetuximab.
    Tscharner GG; Bühler S; Borner M; Hunziker T
    Dermatology; 2006; 213(1):37-9. PubMed ID: 16778425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosaceiform eruption induced by cetuximab.
    Fernández-Torres R; Martínez Gomez W; Cuevas Santos J; Paradela S; Fonseca Capdevila E
    Eur J Dermatol; 2010; 20(3):392-3. PubMed ID: 20172848
    [No Abstract]   [Full Text] [Related]  

  • 29. Scalp pustules in a patient receiving chemotherapy.
    Chiu HY; Chiu HC
    JAMA; 2013 Sep; 310(10):1068-9. PubMed ID: 24026603
    [No Abstract]   [Full Text] [Related]  

  • 30. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption.
    Scope A; Lieb JA; Dusza SW; Phelan DL; Myskowski PL; Saltz L; Halpern AC
    J Am Acad Dermatol; 2009 Oct; 61(4):614-20. PubMed ID: 19646778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
    Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
    J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acneiform eruption induced by cetuximab.
    Cotena C; Gisondi P; Colato C; Girolomoni G
    Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe acneiform rash.
    Yamamoto DS; Viale PH; Zhao G
    Clin J Oncol Nurs; 2004 Dec; 8(6):654-6. PubMed ID: 15637959
    [No Abstract]   [Full Text] [Related]  

  • 34. The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
    Wnorowski AM; de Souza A; Chachoua A; Cohen DE
    Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erlotinib-induced dermatologic side-effects.
    Bovenschen HJ; Alkemade JA
    Int J Dermatol; 2009 Mar; 48(3):326-8. PubMed ID: 19261029
    [No Abstract]   [Full Text] [Related]  

  • 36. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
    de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
    Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors.
    Brodell LA; Hepper D; Lind A; Gru AA; Anadkat MJ
    J Cutan Pathol; 2013 Oct; 40(10):865-70. PubMed ID: 23941617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists.
    Hassel JC; Kripp M; Al-Batran S; Hofheinz RD
    Onkologie; 2010; 33(3):94-8. PubMed ID: 20215799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
    Santoro F; Cozzani E; Parodi A
    J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor.
    Sheu J; Hawryluk EB; Litsas G; Thakuria M; LeBoeuf NR
    Clin Breast Cancer; 2015 Feb; 15(1):e77-81. PubMed ID: 25445421
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.